Severe pancytopenia in a patient taking low dose methotrexate and probenecid.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 2066953.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid. Clinically significant drug interactions are not frequently cited as risk factors for MTX hematologic toxicity. As low dose MTX is gaining increasing popularity in rheumatologic practice, these potentially serious interactions should be considered.
Medical subject headings
- Methotrexate
- Pancytopenia
- Probenecid